GEN Exclusives

More »

GEN News Highlights

More »
Apr 12, 2010

miRagen to Assess RXi’s Technology Against miRNA Targets of Interest

  • RXi Pharmaceuticals and miRagen Therapeutics entered into a collaboration to evaluate RXi’s rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds.

    RXi says that its version of RNAi compounds, developed on the rxRNA platform, provide an alternative to siRNAs. These include rxRNAori™, rxRNAsolo™, and sd-rxRNA™ (self-delivering RNA), which are distinct from classic siRNAs.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?